Vanda Pharmaceuticals

$14.39
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-0.69%) Today

$0.00 (0.00%) As of 12:00 PM UTC after-hours

Why Robinhood?

You can buy or sell VNDA and other stocks, options, and ETFs commission-free!

About VNDA

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC. The listed name for VNDA is Vanda Pharmaceuticals Inc. Common Stock.

CEO

Mihael Hristos Polymeropoulos

Employees

284

Headquarters

Washington, District of Columbia

Founded

2002

Market Cap

774.79M

Price-Earnings Ratio

41.22

Dividend Yield

—

Average Volume

452.11K

High Today

$14.88

Low Today

$14.17

Open Price

$14.29

Volume

380.00K

52 Week High

$14.88

52 Week Low

$7.12

Collections

VNDA Earnings

$0.00

$0.09

$0.19

$0.28

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 23, After Hours